Innovative Vaccines | Arcturus Therapeutics leverages its LUNAR platform to develop next-gen mRNA vaccines, positioning itself at the forefront of infectious disease prevention |
Strategic Alliances | Explore Arcturus' $4.3 billion partnership with CSL, showcasing the company's potential for substantial revenue growth and market expansion |
Market Challenges | Delve into Arcturus' strategy to differentiate its products in a competitive landscape, balancing innovation against established pharmaceutical giants |
Financial Outlook | Analyst price targets range from $72 to $87, reflecting optimism amid near-term financial pressures and the promise of milestone-driven growth |
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Metrics to compare | ARCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARCTPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.1x | −2.2x | −0.6x | |
PEG Ratio | 0.04 | 0.00 | 0.00 | |
Price/Book | 2.2x | 0.7x | 2.6x | |
Price / LTM Sales | 3.5x | 11.7x | 3.2x | |
Upside (Analyst Target) | 244.5% | 224.5% | 43.9% | |
Fair Value Upside | Unlock | 29.0% | 7.8% | Unlock |